Literature DB >> 16357188

Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.

Arminder S Jassar1, Eiji Suzuki, Veena Kapoor, Jing Sun, Michael B Silverberg, Lumei Cheung, Marie D Burdick, Robert M Strieter, Lai-Ming Ching, Larry R Kaiser, Steven M Albelda.   

Abstract

5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is a small molecule in the flavanoid class that has antitumor activity thought to be due to ability to induce high local levels of tumor necrosis factor (TNF)-alpha that disrupt established blood vessels within tumors. The drug has completed phase 1 testing in humans and is currently in phase 2 trials in combination with chemotherapy. Although characterized as a "vascular disrupting agent," there are some studies suggesting that DMXAA also has effects on the immune system that are important for its efficacy. The goal of this study was to carefully define the immune effects of DMXAA in a series of murine lung cancer and mesothelioma cell lines with varying immunologic characteristics. We show that DMXAA efficiently activated tumor-associated macrophages to release a variety of immunostimulatory cytokines and chemokines, including TNF-alpha; IFN-inducible protein-10; interleukin-6; macrophage inflammatory protein-2; monocyte chemotactic protein-1; and regulated on activation, normal T-cell expressed, and secreted. DMXAA treatment was highly effective in both small and large flank tumors. Animals cured of tumors by DMXAA generated a systemic memory response and were resistant to tumor cell rechallenge. DMXAA treatment led to initial tumor infiltration with macrophages that was followed by an influx of CD8(+) T cells. These CD8(+) T cells were required for antitumor efficacy because tumor inhibitory activity was lost in nude mice, mice depleted of CD8(+) T cells, and perforin knockout mice, but not in CD4(+) T-cell-depleted mice. These data show that activation of tumor-associated macrophages by DMXAA is an efficient way to generate a CD8(+) T-cell-dependent antitumor immune response even in animals with relatively nonimmunogenic tumors. Given these properties, DMXAA might also be useful in boosting other forms of immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16357188     DOI: 10.1158/0008-5472.CAN-05-1658

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

1.  Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation.

Authors:  Jing Sun; Liang-Chuan S Wang; Zvi G Fridlender; Veena Kapoor; Guanjun Cheng; Lai-Ming Ching; Steven M Albelda
Journal:  Biochem Pharmacol       Date:  2011-07-26       Impact factor: 5.858

Review 2.  Progress in tumor-associated macrophage (TAM)-targeted therapeutics.

Authors:  Chayanon Ngambenjawong; Heather H Gustafson; Suzie H Pun
Journal:  Adv Drug Deliv Rev       Date:  2017-04-25       Impact factor: 15.470

3.  Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.

Authors:  Zvi G Fridlender; Jing Sun; Sunil Singhal; Veena Kapoor; Guanjun Cheng; Eiji Suzuki; Steven M Albelda
Journal:  Mol Ther       Date:  2010-08-03       Impact factor: 11.454

4.  5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential.

Authors:  Daniel Prantner; Darren J Perkins; Wendy Lai; Mark S Williams; Shruti Sharma; Katherine A Fitzgerald; Stefanie N Vogel
Journal:  J Biol Chem       Date:  2012-10-01       Impact factor: 5.157

5.  Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells.

Authors:  Zvi G Fridlender; Veena Kapoor; George Buchlis; Guanjun Cheng; Jing Sun; Liang-Chuan S Wang; Sunil Singhal; Linda A Snyder; Steven M Albelda
Journal:  Am J Respir Cell Mol Biol       Date:  2010-04-15       Impact factor: 6.914

6.  The STING agonist 5,6-dimethylxanthenone-4-acetic acid (DMXAA) stimulates an antiviral state and protects mice against herpes simplex virus-induced neurological disease.

Authors:  Stacey Cerón; Brian J North; Sean A Taylor; David A Leib
Journal:  Virology       Date:  2019-01-06       Impact factor: 3.616

7.  Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy.

Authors:  Samuel Kim; George Buchlis; Zvi G Fridlender; Jing Sun; Veena Kapoor; Guanjun Cheng; Andrew Haas; Hung Kam Cheung; Xiamei Zhang; Michael Corbley; Larry R Kaiser; Leona Ling; Steven M Albelda
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

8.  Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.

Authors:  Joseph Conlon; Dara L Burdette; Shruti Sharma; Numana Bhat; Mikayla Thompson; Zhaozhao Jiang; Vijay A K Rathinam; Brian Monks; Tengchuan Jin; T Sam Xiao; Stefanie N Vogel; Russell E Vance; Katherine A Fitzgerald
Journal:  J Immunol       Date:  2013-04-12       Impact factor: 5.422

9.  Refractoriness of interferon-beta signaling through NOD1 pathway in mouse respiratory epithelial cells using the anticancer xanthone compound.

Authors:  Zaifang Yu; Jarrod D Predina; Guanjun Cheng
Journal:  World J Biol Chem       Date:  2013-05-26

10.  Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.

Authors:  Vassiliki Saloura; Liang-Chuan S Wang; Zvi G Fridlender; Jing Sun; Guanjun Cheng; Veena Kapoor; Daniel H Sterman; Ronald N Harty; Atsushi Okumura; Glen N Barber; Richard G Vile; Mark J Federspiel; Stephen J Russell; Leslie Litzky; Steven M Albelda
Journal:  Hum Gene Ther       Date:  2010-01       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.